Platelet activation as a novel mechanism of atherothrombotic risk in chronic obstructive pulmonary disease

References

• Vanfleteren LW, Spruit MA, Groenen M et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 187, 728–735 (2013).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Buring JE et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342, 836–843 (2000).
   PubMed Web of Science ®Google Scholar
• Curkendall SM, DeLuise C, Jones JK et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann. Epidemiol. 16, 63–70 (2006).
   PubMed Web of Science ®Google Scholar
• MacNee W, Maclay J, Mcallister D. Cardiovascular injury and repair in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 5, 824–833 (2008).
   PubMedGoogle Scholar
• Sin DD, Anthonisen NR, Soriano JB et al. Mortality in COPD: role of comorbidities. Eur. Respir. J. 28, 1245–1257 (2006).
   PubMed Web of Science ®Google Scholar
• McAllister DA, Maclay JD, Mills NL et al. Diagnosis of myocardial infarction following hospitalisation for exacerbation of COPD. Eur. Respir. J. 39, 1097–1103 (2012).
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Hurst JR, Smith CJ et al. Increased risk of myocardical infarction and stroke following exacerbation of COPD. Chest 137(5), 1091–1097 (2010).
   PubMed Web of Science ®Google Scholar
• Hoffman M. Remodeling the blood coagulation cascade. J. Thromb. Thrombolysis, 16(1–2), 17–20 (2003).
   PubMed Web of Science ®Google Scholar
• Di Santo A, Amore C, Dell'Elba G et al. Glycogen synthase kinase-3 negatively regulates tissue factor expression in monocytes interacting with activated platelets. J. Thromb. Haemost. 9(5), 1029–1039 (2011).
   PubMedGoogle Scholar
• Schumacher A, Liebers U, John M, et al. P-selectin glycoprotein ligand-1 (PSGL-1) is up-regulated on leucocytes from patients with chronic obstructive pulmonary disease. Clin. Exp. Immunol. 142(2), 370–376 (2005).
   PubMed Web of Science ®Google Scholar
• Davi G, Patrono C. Platelet activation and atherothrombosis. N. Engl. J. Med. 357, 2482–2494 (2007).
   PubMed Web of Science ®Google Scholar
• Duvoix A, Dickens J, Haq I et al. Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax 68, 670–676 (2013) .
   PubMed Web of Science ®Google Scholar
• Dahl M, Tybjaerg-Hansen A, Vestbo J et al. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 164, 1008–1011 (2001).
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 363, 1128–1138 (2010).
   PubMed Web of Science ®Google Scholar
• Stec JJ, Silbershatz H, Tofler GH et al. Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population. Circulation 102, 1634–1638 (2000).
   PubMed Web of Science ®Google Scholar
• Lambert MP, Sachais BS, Kowalska MA. Chemokines and thrombogenicity. Thromb. Haemost. 97, 722–729 (2007).
   PubMedGoogle Scholar
• Wedzicha JA, Syndercombe-Court, Tan KC. Increased platelet aggregate formation in patients with chronic airflow obstruction and hypoxaemia. Thorax 46, 504–507 (1991).
   PubMed Web of Science ®Google Scholar
• Patrono C, Patrignani P, Rocca B et al. Characterization of biochemical and functional effects of antiplatelet drugs as a key to their clinical development. Thromb. Haemost. 74, 396–400 (1995).
   PubMedGoogle Scholar
• Rolin S, Masereel B, Dogne JM. Prostanoids as pharmacological targets in COPD and asthma. Eur. J. Pharmacol. 533, 89–100 (2006).
   PubMed Web of Science ®Google Scholar
• Davì G, Basili S, Vieri M et al. Enhanced thromboxane biosynthesis in patients with chronic obstructive pulmonary disease. The Chronic Obstructive Bronchitis and Haemostasis Study Group. Am. J. Respir. Crit. Care Med. 156, 1794–1799 (1997).
   PubMed Web of Science ®Google Scholar
• Ponicke K, Sternitzky R, Mest HJ. Stimulation of aggregation and thromboxane A2 formation of human platelets by hypoxia. Prostaglandins Leukot Med. 29, 49–59 (1987).
   PubMedGoogle Scholar
• Patrono C. Thromboxane synthesis inhibitors and receptor antagonists. Thromb. Res. Suppl. 11, 15–23 (1990).
   PubMedGoogle Scholar
• Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J. Clin. Invest. 115, 3378–3384 (2005).
   PubMed Web of Science ®Google Scholar
• Boots AW, Haenen GR, Bast A. Oxidant metabolism in chronic obstructive pulmonary disease. Eur. Respir. J. Suppl. 46, 14s–27s (2003).
   PubMedGoogle Scholar
• Nowak D, Kasielski M, Antczak A et al. Increased content of thiobarbituric acid-reactive substances and hydrogen peroxide in the expired breath condensate of patients with stable chronic obstructive pulmonary disease: no significant effect of cigarette smoking. Respir. Med. 93, 389–396 (1999).
   PubMed Web of Science ®Google Scholar
• Nowak D, Kalucka S, Bialasiewicz P et al. Exhalation of H2O2 and thiobarbituric acid reactive substances (TBARs) by healthy subjects. Free Radic. Biol. Med. 30, 178–186 (2001).
   PubMed Web of Science ®Google Scholar
• Praticò D, Basili S, Vieri M et al. Chronic obstructive pulmonary disease is associated with an increase in urinary levels of isoprostane F2alpha-III, an index of oxidant stress. Am. J. Respir. Crit. Care Med. 158, 1709–1714 (1998).
   PubMed Web of Science ®Google Scholar
• Devaraj S, Hirany SV, Burk RF et al. Divergence between LDL oxidative susceptibility and urinary F(2)-isoprostanes as measures of oxidative stress in type 2 diabetes. Clin. Chem. 47, 1974–1979 (2001).
   PubMed Web of Science ®Google Scholar
• Pernerstorfer T, Stohlawetz P, Stummvoll G et al. Low-dose aspirin does not lower in vivo platelet activation in healthy smokers. Br. J. Haematol. 102, 1229–1231 (1998).
   PubMed Web of Science ®Google Scholar
• Hioki Y, Aoki N, Kawano K et al. Acute effects of cigarette smoking on platelet-dependent thrombin generation. Eur. Heart J. 22, 56–61 (2001).
   PubMed Web of Science ®Google Scholar
• Hung J, Lam JYT, Lacoste L et al. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation, 92, 2432–2436 (1995).
   PubMed Web of Science ®Google Scholar
• Harding SA, Sarma J, Josephs DH et al. Upregulation of the CD40/CD40 ligand dyad and platelet–monocyte aggregation in cigarette smokers. Circulation 109, 1926–1929 (2004).
   PubMed Web of Science ®Google Scholar
• Heeschen C, Dimmeler S, Hamm CW et al.; CAPTURE Study Investigators. Soluble CD40 ligand in acute coronary syndromes. N. Engl. J. Med. 348, 1104–1111 (2003).
   PubMed Web of Science ®Google Scholar
• André P, Nannizzi-Alaimo L, Prasad SK et al. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 106, 896–899 (2002).
   PubMed Web of Science ®Google Scholar
• Falco A, Romano M, Iapichino L et al. Increased solubile CD40 ligand levels in cystic fibrosis. J. Thromb. Haemost. 2, 557–560 (2004).
   PubMedGoogle Scholar
• Fimognari FL, Scarlata S, Conte ME et al. Mechanisms of atherothrombosis in chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 3(1), 89–96 (2008).
   PubMedGoogle Scholar
• Miller GJ, Bauer KA, Cooper JA et al. Activation of the coagulant pathway in cigarette smokers. Thromb. Haemost. 79, 549–553 (1998).
   PubMed Web of Science ®Google Scholar
• Dominick J. Angiolillo, Goto S. Basic principles of platelet biology and clinical implications. Circ. J. 74, 597–607 (2010).
   PubMedGoogle Scholar
• da Costa Martins PA, van Gils JM, Mol A et al. Platelet binding to monocytes increases the adhesive properties of monocytes by up-regulating the expression and functionality of beta1 and beta2 integrins. J. Leukoc. Biol. 79, 499–507 (2006).
   PubMed Web of Science ®Google Scholar
• Schober A, Manka D, von Hundelshausen P et al. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation 106, 1523–1529 (2002).
   PubMed Web of Science ®Google Scholar
• Zarbock A, Polanowska-Grabowska RK, Ley K. Platelet-neutrophil-interactions: linking hemostasis and inflammation. Blood Rev. 21, 99–111 (2007).
   PubMed Web of Science ®Google Scholar
• Alciato F, Sainaghi PP, Sola D et al. TNF-alpha, IL-6, and IL-1 expression is inhibited by GAS6 in monocytes/macrophages. J. Leukoc. Biol. 87(5), 869 (2010).
   PubMed Web of Science ®Google Scholar
• Muñoz X, Sumoy L, Ramírez-Lorca R et al. Human vitamin K-dependent GAS6: gene structure, allelic variation, and association with stroke. Hum. Mutat. 23(5), 506–512 (2004).
   PubMed Web of Science ®Google Scholar
• Hurtado B, Abasolo N, Muñoz X et al. Association study between polymorphims in GAS6-TAM genes and carotid atherosclerosis. Thromb. Haemost. 104(3), 592–598 (2010).
   PubMed Web of Science ®Google Scholar
• van Eeden SF, Sin DD. Chronic obstructive pulmonary disease: a chronic systemic inflammatory disease. Respiration 75, 224–238 (2008).
   PubMed Web of Science ®Google Scholar
• Maclay JD, McAllister DA, Johnston S et al. Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax 66, 769–774 (2011).
   PubMed Web of Science ®Google Scholar
• De Castro J, Hernandez-Hernandez A, Rodriguez MC et al. Comparison of changes in erythrocyte and platelet phospholipid and fatty acid composition and protein oxidation in chronic obstructive pulmonary disease and asthma. Platelets 18, 43–51 (2007).
   PubMed Web of Science ®Google Scholar
• Ferroni P, Basili S, Martini F et al, Soluble P-selectin as a marker of platelet hyperactivity in patients with chronic obstructive pulmonary disease. J. Invest. Med. 48, 21–27 (2000).
   PubMed Web of Science ®Google Scholar
• Walter RE, Wilk JB, Larson MG et al. Systemic inflammation and COPD: the Framingham Heart Study. Chest 133, 19–25 (2008).
   PubMed Web of Science ®Google Scholar
• Sarma J, Laan CA, Alam S et al. Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation 105, 2166–2171 (2002).
   PubMed Web of Science ®Google Scholar
• Christie DJ, Kottke-Marchant K, Gorman RT. Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy. Platelets 19, 104–110 (2008).
   PubMed Web of Science ®Google Scholar
• Gianetti J, Parri MS, Sbrana S et al. Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: a 6 months prospective study. Thromb. Res. 118, 487–493 (2006).
   PubMed Web of Science ®Google Scholar
• Humbert M, Morrell N, Archer S et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43, 13–24 (2004).
   PubMed Web of Science ®Google Scholar
• Maclay JD, McAllister DA, Mills NL et al. Vascular dysfunction in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 180, 513–520 (2009).
   PubMed Web of Science ®Google Scholar
• Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J. Clin. Invest. 115, 3378–3384 (2005).
   PubMed Web of Science ®Google Scholar
• Borgel D, Clauser S, Bornstain C et al. Elevated growth-arrest-specific protein 6 plasma levels in patients with severe sepsis. Crit. Care Med. 34, 219–222 (2006).
   PubMed Web of Science ®Google Scholar
• Sainaghi PP, Alciato F, Carnieletto S et al. Gas evaluation in patients with acute dyspnea due to suspected pulmonary embolism. Respir. Med. 103(4), 589–594 (2009).
   PubMedGoogle Scholar
• Vaidyula VR, Boden G, Rao AK. Platelet and monocyte activation by hyperglycemia and hyperinsulinemia in healthy subjects. Platelets 17, 577e85 (2006).
   Google Scholar
• Smeeth L, Thomas SL, Hall AJ et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N. Engl. J. Med. 351, 2611e18 (2004).
   Google Scholar
• Crisafulli E, Marietta M, Venturelli E et al. Platelets count in chronic obstructive pulmonary disease [abstract]. Eur. Respir. J. 40(Suppl.), 76s (2012).
   Google Scholar
• Ly HQ, Kirtane AJ, Murphy SA et al. Association of platelet counts on presentation and clinical outcomes in ST-elevation myocardial infarction (from the TIMI Trials). Am. J. Cardiol. 98, 1–5 (2006).
   PubMed Web of Science ®Google Scholar
• Vizioli L, Muscari S, Muscari A. The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. Int. J. Clin. Pract. 63, 1509–1515 (2009).
   PubMed Web of Science ®Google Scholar
• Steiropoulos P, Papanas N, Nena E et al. Mean platelet volume and platelet distribution width in patients with chronic obstructive pulmonary disease: the role of comorbidities. Platelets 23, 447–454 (2012).
   PubMedGoogle Scholar
• Cui H, Liu L, Wei Z et al. Clinical value of mean platelet volume for impaired cardiopulmonary function in very old male patients with chronic obstructive pulmonary disease. Arch. Gerontol. Geriatr. 54(2), 109–112 (2012).
   PubMed Web of Science ®Google Scholar
• Ulasli SS, Ozyurek BA, Yilmaz EB et al. Mean platelet volume as an inflammatory marker in acute exacerbation of chronic obstructive pulmonary disease. Pol. Arch. Med. Wewn. 122(6), 284–290 (2012).
   PubMed Web of Science ®Google Scholar
• Biljak VR, Pancirov D, Cepelak I et al. Platelet count, mean platelet volume and smoking status in stable chronic obstructive pulmonary disease. Platelets 22(6), 466–470 (2011).
   PubMed Web of Science ®Google Scholar
• Rutten FH, Cramer MJ, Lammers JW et al. Heart failure chronic obstructive pulmonary disease: an ignored combination? Eur. J. Heart Fail. 8, 706–711 (2006).
   PubMed Web of Science ®Google Scholar
• Klinkhardt U, Bauersachs R, Adams J et al. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clin. Pharmacol. Ther. 73, 232–241 (2003).
   PubMed Web of Science ®Google Scholar
• Pettersen AÅ, Seljeflot I, Abdelnoor M et al. High on-aspirin platelet reactivity and clinical outcome in patients with stable coronary artery disease: results from ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial). J. Am. Heart Assoc. 1(3), e000703 (2012).
   Web of Science ®Google Scholar
• Mora S, Wenger NK, Demicco DA et al. Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study. Circulation 125(16), 1979–1987 (2012).
   PubMed Web of Science ®Google Scholar
• Briasoulis A, Tousoulis D, Bakogiannis C et al. Novel anti-platelet agents for the treatment of stable angina pectoris. Curr. Pharm. Des. 19(9), 1581–1586 (2013).
   PubMedGoogle Scholar
• Barrett NE, Holbrook L, Jones S et al. Future innovations in anti-platelet therapies. Br. J. Pharmacol. 154, 918–939 (2008).
   PubMed Web of Science ®Google Scholar
• Sin DD, Lacy P, York E et al. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 170, 760–765 (2004).
   PubMed Web of Science ®Google Scholar
• Sin DD, Wu L, Anderson JA, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 60, 992–997 (2005).
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Kjekshus J, Berg K et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Atheroscler. Suppl. 5(3), 81–87 (2004).
   PubMed Web of Science ®Google Scholar
• Macie C, Wooldrage K, Manfreda J et al. Inhaled corticosteroids and mortality in COPD. Chest 130, 640–646 (2006).
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B et al; TORCH investigators. Salmeterol and fl uticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 356, 775–789 (2007).
   PubMed Web of Science ®Google Scholar
• Eickelberg O, Roth M, Lorx R et al. Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fi broblasts and vascular smooth muscle cells. J. Biol. Chem. 274, 1005–1010 (1999).
   PubMed Web of Science ®Google Scholar
• Afessa B, Morales IJ, Scanlon PD, Peters SG. Prognostic factors, clinical course, and hospital outcome of patients with chronic obstructive pulmonary disease admitted to an intensive care unit for acute respiratory failure. Crit. Care Med. 30, 1610–1615 (2002).
   PubMed Web of Science ®Google Scholar
• Lahousse L, Van der Bouwhuijsen QJA, Loth DV et al. Chronic obstructive pulmonary disease and lipid core carotid artery plaques in the elderly. The Rotterdam Study. Am. J. Respir. Crit. Care Med. 187, 58–64 (2013).
   PubMed Web of Science ®Google Scholar